HUP0401934A2 - Enantiomerekben dúsított demetil- és didemetil- citalopram metabolitok alkalmazása depresszió és más központi idegrendszeri rendellenességek esetében - Google Patents

Enantiomerekben dúsított demetil- és didemetil- citalopram metabolitok alkalmazása depresszió és más központi idegrendszeri rendellenességek esetében

Info

Publication number
HUP0401934A2
HUP0401934A2 HU0401934A HUP0401934A HUP0401934A2 HU P0401934 A2 HUP0401934 A2 HU P0401934A2 HU 0401934 A HU0401934 A HU 0401934A HU P0401934 A HUP0401934 A HU P0401934A HU P0401934 A2 HUP0401934 A2 HU P0401934A2
Authority
HU
Hungary
Prior art keywords
enantiomerically enriched
didesmethyl
desmethyl
citalopram
metabolites
Prior art date
Application number
HU0401934A
Other languages
English (en)
Inventor
Larry R. Bush
Mark G. Currie
Chris H. Senanayake
Kevin Q. Fang
Original Assignee
Sepracor Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc. filed Critical Sepracor Inc.
Publication of HUP0401934A2 publication Critical patent/HUP0401934A2/hu
Publication of HUP0401934A3 publication Critical patent/HUP0401934A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
    • C07D317/20—Free hydroxyl or mercaptan

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A találmány tárgyát (I) és (II) képletű vegyületek, racém,enantiomeresen dúsított vagy optikailag tiszta alakban, előállításieljárásaik, az ezeket tartalmazó gyógyászatilag elfogadhatókészítmények, amelyek egy vagy több, az előbbiekben említettvegyületet tartalmaznak gyógyászatilag elfogadható mennyiségben, ésezen gyógyszerkészítmények alkalmazása a szerotonin újrafelvételgátlásával terápiásan előnyösen befolyásolható egy vagy többrendellenesség, diszfunkció vagy betegség kezelésére, valamint egyterápiás kit képezi. Ó
HU0401934A 2001-11-08 2002-11-05 Methods for treating depression and other cns disorders using enantiomerically enriched desmethyl- and didesmethyl-metabolites of citalopram HUP0401934A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33760801P 2001-11-08 2001-11-08
PCT/US2002/035408 WO2003040121A1 (en) 2001-11-08 2002-11-05 Methods for treating depression and other cns disorders using enantiomerically enriched desmethyl- and didesmethyl-metabolites of citalopram

Publications (2)

Publication Number Publication Date
HUP0401934A2 true HUP0401934A2 (hu) 2005-01-28
HUP0401934A3 HUP0401934A3 (en) 2007-05-29

Family

ID=23321236

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0401934A HUP0401934A3 (en) 2001-11-08 2002-11-05 Methods for treating depression and other cns disorders using enantiomerically enriched desmethyl- and didesmethyl-metabolites of citalopram

Country Status (17)

Country Link
US (1) US20040266864A1 (hu)
EP (1) EP1446396A1 (hu)
JP (1) JP2005510518A (hu)
KR (1) KR20050043776A (hu)
CN (1) CN1705654A (hu)
AU (1) AU2002356903A2 (hu)
BR (1) BR0213949A (hu)
CA (1) CA2465186A1 (hu)
HU (1) HUP0401934A3 (hu)
IL (1) IL161617A0 (hu)
MX (1) MXPA04004368A (hu)
NO (1) NO20042013L (hu)
NZ (1) NZ532478A (hu)
PL (1) PL368452A1 (hu)
RU (1) RU2004117211A (hu)
WO (1) WO2003040121A1 (hu)
ZA (1) ZA200403409B (hu)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7884136B2 (en) * 2005-06-27 2011-02-08 Biovail Laboratories International S.R.L. Modified-release formulations of a bupropion salt
WO2007027476A2 (en) * 2005-08-26 2007-03-08 Xenoport, Inc. Treating premature ejaculation using gabapentin and pregabalin prodrugs
JP2010512314A (ja) * 2006-12-08 2010-04-22 ゼノポート，インコーポレーテッド 疾患を治療するためのｇａｂａアナログのプロドラッグの使用
KR101103118B1 (ko) * 2007-11-02 2012-01-04 동아제약주식회사 신규한 1,3-디히드로-5-이소벤조퓨란카르보니트릴 유도체 화합물 및 이를 함유하는 조루증 치료용 약학조성물
US9056850B2 (en) 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
EP2376072A1 (en) * 2008-12-29 2011-10-19 Tartu Ülikool (University Of Tartu) Arginase inhibitors for the treatment of depression
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
PL2488515T3 (pl) 2009-10-14 2017-07-31 Janssen Pharmaceutica Nv Sposób wytwarzania związków użytecznych jako inhibitory sglt2
EP2377522B1 (en) * 2010-04-15 2013-01-16 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Orally disintegrating tablet formulations of mirtazapine and process for preparing the same
MY187718A (en) 2010-05-11 2021-10-14 Janssen Pharmaceutica Nv Pharmaceutical formulations
WO2012140120A1 (en) 2011-04-13 2012-10-18 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of sglt2
KR101427221B1 (ko) * 2012-08-29 2014-08-13 주식회사 에스텍파마 플루복사민 자유 염기의 정제방법 및 이를 이용한 고순도 플루복사민 말레이트의 제조방법
UA122222C2 (uk) * 2015-02-11 2020-10-12 Суновіон Фармасьютикалз Інк. Сполуки 1-гетероцикліл-ізохроманілу і аналоги для лікування розладів цнс

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1017415C1 (nl) * 2000-02-24 2001-05-18 Lundbeck & Co As H Werkwijze voor de bereiding van Citalopram.
IES20010157A2 (en) * 2000-03-03 2002-03-06 Lundbeck & Co As H Method for the preparation of citalopram
EA200200968A1 (ru) * 2000-03-13 2003-02-27 Х.Лундбекк А/С Поэтапное алкилирование 5-замещенных 1-(4-фторфенил)-1,3-дигидроизобензофуранов
KR100439329B1 (ko) * 2000-12-22 2004-07-07 하. 룬트벡 아크티에 셀스카브 순수한 시탈로프람의 제조방법

Also Published As

Publication number Publication date
CA2465186A1 (en) 2003-05-15
HUP0401934A3 (en) 2007-05-29
KR20050043776A (ko) 2005-05-11
WO2003040121A1 (en) 2003-05-15
ZA200403409B (en) 2005-10-26
IL161617A0 (en) 2004-09-27
AU2002356903A2 (en) 2003-05-19
JP2005510518A (ja) 2005-04-21
PL368452A1 (en) 2005-03-21
CN1705654A (zh) 2005-12-07
MXPA04004368A (es) 2004-08-11
NO20042013L (no) 2004-05-14
EP1446396A1 (en) 2004-08-18
RU2004117211A (ru) 2005-03-27
US20040266864A1 (en) 2004-12-30
NZ532478A (en) 2007-02-23
BR0213949A (pt) 2004-08-31

Similar Documents

Publication Publication Date Title
HUP0401934A2 (hu) Enantiomerekben dúsított demetil- és didemetil- citalopram metabolitok alkalmazása depresszió és más központi idegrendszeri rendellenességek esetében
HUP0103377A2 (hu) Függőség és függőséggel kapcsolatos viselkedés kezelése
HUP0300030A2 (en) Bupropion metabolites and methods of their synthesis and use and pharmaceutical compositions containing them and and their use
NO20093464L (no) Nye medikamentblandinger basert pa anti-cholinergisk effektive forbindelser og beta-mimetika
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
HUP0400782A2 (hu) Antikolinergikumokon és PDE-IV inhibitorokon alapuló új gyógyszerkészítmények
HUP0301447A2 (hu) Tiotrópium- és salmeterolsókat tartalmazó kombinációs gyógyszerkészítmények
ATE492279T1 (de) Bupropinmetaboliten zur behandlung von dementia und anderen zerebrovasckulären erkrankungen
DE60216830D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen
HUP0301281A2 (hu) Új gyógyászati készítmény
NO20035474D0 (no) Prodrugs av GABA-analoger, sammensetninger og anvendelse derav
TW200510375A (en) New compounds
MY134480A (en) 4-pyrrolidino-phenyl-benzyl ether derivatives
NO20100334L (no) Behandling av nevrotiske forstyrrelser
HUP0202671A2 (hu) Ketotifen optikailag aktív izomerei és aktív metabolitjai
DE60320095D1 (de) Zusammensetzungen zur behandlung von hauterkrankungen
HUP0101901A2 (hu) Gyógyászati készítmény nehezen kezelhető depresszió kombinált gyógyászati kezelésére, valamint kombinált kezelési eljárás
EA200501865A1 (ru) Аналоги тиовольфраматов и их применение
HUP0204097A2 (hu) Guanozin-3',5'-monofoszfát-foszfodiészteráz inhibitorok alkalmazása diabetikus fekélyek kezelésére szolgáló készítmények előállítására
HUP0204551A2 (hu) Eljárás a pikkelysömör kezelésére
SE9804126D0 (sv) New pharmaceutical composition
ES2187030T3 (es) Una nueva sal.
HUP0103712A2 (hu) Paroxetin sók, eljárás az előállításukra és gyógyászati alkalmazásuk
HUP0402267A2 (hu) Eljárás csontrendellenességek kezelésére
HUP0402298A2 (hu) Dezoxipeganin alkalmazása klinikai depresszió kezelésére

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished